Antimicrobial-Resistant Pathogens in Intensive Care Units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006

ABSTRACT Between 1 September 2005 and 30 June 2006, 19 medical centers collected 4,180 isolates recovered from clinical specimens from patients in intensive care units (ICUs) in Canada. The 4,180 isolates were collected from 2,292 respiratory specimens (54.8%), 738 blood specimens (17.7%), 581 wound/tissue specimens (13.9%), and 569 urinary specimens (13.6%). The 10 most common organisms isolated from 79.5% of all clinical specimens were methicillin-susceptible Staphylococcus aureus (MSSA) (16.4%), Escherichia coli (12.8%), Pseudomonas aeruginosa (10.0%), Haemophilus influenzae (7.9%), coagulase-negative staphylococci/Staphylococcus epidermidis (6.5%), Enterococcus spp. (6.1%), Streptococcus pneumoniae (5.8%), Klebsiella pneumoniae (5.8%), methicillin-resistant Staphylococcus aureus (MRSA) (4.7%), and Enterobacter cloacae (3.9%). MRSA made up 22.3% (197/884) of all S. aureus isolates (90.9% of MRSA were health care-associated MRSA, and 9.1% were community-associated MRSA), while vancomycin-resistant enterococci (VRE) made up 6.7% (11/255) of all enterococcal isolates (88.2% of VRE had the vanA genotype). Extended-spectrum β-lactamase (ESBL)-producing E. coli and K. pneumoniae occurred in 3.5% (19/536) and 1.8% (4/224) of isolates, respectively. All 19 ESBL-producing E. coli isolates were PCR positive for CTX-M, with blaCTX-M-15 occurring in 74% (14/19) of isolates. For MRSA, no resistance against daptomycin, linezolid, tigecycline, and vancomycin was observed, while the resistance rates to other agents were as follows: clarithromycin, 89.9%; clindamycin, 76.1%; fluoroquinolones, 90.1 to 91.8%; and trimethoprim-sulfamethoxazole, 11.7%. For E. coli, no resistance to amikacin, meropenem, and tigecycline was observed, while resistance rates to other agents were as follows: cefazolin, 20.1%; cefepime, 0.7%; ceftriaxone, 3.7%; gentamicin, 3.0%; fluoroquinolones, 21.1%; piperacillin-tazobactam, 1.9%; and trimethoprim-sulfamethoxazole, 24.8%. Resistance rates for P. aeruginosa were as follows: amikacin, 2.6%; cefepime, 10.2%; gentamicin, 15.2%; fluoroquinolones, 23.8 to 25.5%; meropenem, 13.6%; and piperacillin-tazobactam, 9.3%. A multidrug-resistant (MDR) phenotype (resistance to three or more of the following drugs: cefepime, piperacillin-tazobactam, meropenem, amikacin or gentamicin, and ciprofloxacin) occurred frequently in P. aeruginosa (12.6%) but uncommonly in E. coli (0.2%), E. cloacae (0.6%), or K. pneumoniae (0%). In conclusion, S. aureus (MSSA and MRSA), E. coli, P. aeruginosa, H. influenzae, Enterococcus spp., S. pneumoniae, and K. pneumoniae are the most common isolates recovered from clinical specimens in Canadian ICUs. A MDR phenotype is common for P. aeruginosa isolates in Canadian ICUs.

[1]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[2]  M. Mulvey,et al.  Enterococcus faecium N03-0072 carries a new VanD-type vancomycin resistance determinant: characterization of the VanD5 operon. , 2004, The Journal of antimicrobial chemotherapy.

[3]  H. Chambers,et al.  Community-associated MRSA--resistance and virulence converge. , 2005, The New England journal of medicine.

[4]  B. Farr.  What To Think If the Results of the National Institutes of Health Randomized Trial of Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus Control Measures Are Negative (and Other Advice to Young Epidemiologists): A Review and an Au Revoir , 2006, Infection Control & Hospital Epidemiology.

[5]  K. Laupland,et al.  Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. , 2005, The Journal of antimicrobial chemotherapy.

[6]  P. Nordmann,et al.  Incidence of class A extended-spectrum beta-lactamases in Champagne-Ardenne (France): a 1 year prospective study. , 2007, The Journal of antimicrobial chemotherapy.

[7]  Richard Platt,et al.  Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Mulvey,et al.  Comparative Genomics of Canadian Epidemic Lineages of Methicillin-Resistant Staphylococcus aureus , 2007, Journal of Clinical Microbiology.

[9]  M. Cetron,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.

[10]  M. Mulvey,et al.  Ambler Class A Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella spp. in Canadian Hospitals , 2004, Antimicrobial Agents and Chemotherapy.

[11]  R. Gaynes,et al.  Antimicrobial resistance prevalence rates in hospital antibiograms reflect prevalence rates among pathogens associated with hospital-acquired infections. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Surveillance Report, data summary from January 1996 through December 1997: A report from the National Nosocomial Infections Surveillance (NNIS) System. , 1999, American journal of infection control.

[13]  D. Oliveira,et al.  Multiplex PCR Strategy for Rapid Identification of Structural Types and Variants of the mec Element in Methicillin-Resistant Staphylococcus aureus , 2002, Antimicrobial Agents and Chemotherapy.

[14]  Ronald N. Jones,et al.  Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. , 2007, Diagnostic microbiology and infectious disease.

[15]  R. Weinstein,et al.  Community-associated Methicillin-resistant Staphylococcus aureus , 2006, Emerging infectious diseases.

[16]  M. Kollef,et al.  Surveillance for Vancomycin-Resistant Enterococci: Type, Rates, Costs, and Implications , 2006, Infection Control & Hospital Epidemiology.

[17]  A. Kiss,et al.  Risk Factors Associated With Resistance to Ciprofloxacin in Clinical Bacterial Isolates From Intensive Care Unit Patients , 2007, Infection Control & Hospital Epidemiology.

[18]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[19]  Y. Carmeli,et al.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. , 2007, The Journal of antimicrobial chemotherapy.

[20]  J. Laurila,et al.  Epidemiology of intensive care unit (ICU)‐acquired infections in a 14‐month prospective cohort study in a single mixed Scandinavian university hospital ICU , 2006, Acta anaesthesiologica Scandinavica.

[21]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[22]  S. Leone,et al.  Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist. , 2007, International journal of antimicrobial agents.

[23]  J. Quinn,et al.  Antimicrobial Resistance among Gram-Negative Bacilli Causing Infections in Intensive Care Unit Patients in the United States between 1993 and 2004 , 2007, Journal of Clinical Microbiology.

[24]  P. Rhomberg,et al.  Antimicrobial Resistance among Clinical Isolates ofStreptococcus pneumoniae in the United States during 1999–2000, Including a Comparison of Resistance Rates since 1994–1995 , 2001, Antimicrobial Agents and Chemotherapy.

[25]  L. Harrison,et al.  Active bacterial core surveillance of the emerging infections program network. , 2001, Emerging infectious diseases.

[26]  G. Horsman,et al.  Community-associated Methicillin-resistant Staphylococcus aureus, Canada , 2005, Emerging infectious diseases.

[27]  D. Church,et al.  Molecular Epidemiology of CTX-M-Producing Escherichia coli in the Calgary Health Region: Emergence of CTX-M-15-Producing Isolates , 2007, Antimicrobial Agents and Chemotherapy.

[28]  B. Wickes,et al.  First Report of the Emergence of CTX-M-Type Extended-Spectrum β-Lactamases (ESBLs) as the Predominant ESBL Isolated in a U.S. Health Care System , 2007, Antimicrobial Agents and Chemotherapy.

[29]  D E Low,et al.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.

[30]  D. Cardo,et al.  Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002 , 2007, Public health reports.

[31]  Ronald N. Jones,et al.  Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). , 2006, Diagnostic microbiology and infectious disease.

[32]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[33]  M. Mulvey,et al.  Development of a Canadian Standardized Protocol for Subtyping Methicillin-Resistant Staphylococcus aureus Using Pulsed-Field Gel Electrophoresis , 2001, Journal of Clinical Microbiology.

[34]  Wonkeun Song,et al.  Prevalence of Newer β-Lactamases in Gram-Negative Clinical Isolates Collected in the United States from 2001 to 2002 , 2006, Journal of Clinical Microbiology.

[35]  M. Mulvey,et al.  Outbreak in Alberta of community-acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarceration , 2006, Canadian Medical Association Journal.

[36]  D. Hoban,et al.  Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). , 2003, The Journal of antimicrobial chemotherapy.